Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Medical Genetics

The Science of Diagnosis: Genes and Telomeres

At a Glance

Dyskeratosis congenita diagnosis combines genetic testing with age-adjusted Flow-FISH telomere measurements. Results must be interpreted with symptoms, family history, and other tests because a normal or inconclusive result does not always rule out a telomere biology disorder.

Diagnosing Dyskeratosis Congenita (DC) is a multi-step process that combines clinical observation with specialized laboratory tests. Because DC is a genetically heterogeneous disorder, it can be caused by many different gene mutations and follow various inheritance patterns [1][2].

The Genetics of DC and TBDs

Your genetic report will likely focus on several key genes responsible for maintaining telomeres. The way the condition is passed down through a family—or whether it appears for the first time in an individual (de novo)—depends on which gene is involved [3][4].

  • DKC1 (X-linked): This is the most common form in males. Because it is on the X chromosome, it typically affects males. Females are usually carriers, but they can occasionally show clinical symptoms due to a process called “skewed X-inactivation” [5].
  • TINF2 (Autosomal Dominant): Mutations in this gene are often de novo (newly occurring in the patient, not inherited from parents) and are frequently associated with more severe, early-onset disease [4][6].
  • TERT and TERC (Dominant or Recessive): These genes provide instructions for the telomerase enzyme (TERT) and its RNA template (TERC). They are often associated with incomplete penetrance, meaning one person with the mutation may have severe symptoms while a relative with the same mutation has few or no symptoms [3][7].
  • RTEL1 (Dominant or Recessive): This gene can cause severe childhood forms when two copies are mutated, or later-onset lung and blood issues when only one copy is mutated [8][9].

Important Genetic Concepts

  • Genetic Anticipation: This is a phenomenon where the disease may become more severe or appear at an earlier age in subsequent generations [10]. This can happen if children inherit both the mutated gene and already-shortened telomeres from a parent, though it is not inevitable [11].
  • Incomplete Penetrance: Having the gene mutation does not guarantee you will have all (or any) symptoms of the disease. This makes family screening vital, even for seemingly healthy relatives, guided by a genetic counselor [3][12].

The Diagnostic Role of Flow-FISH Testing

While genetic testing looks for the “blueprint” error, Flow-FISH measures the actual telomeres. This test uses fluorescent markers to measure the length of telomeres in different types of white blood cells [13][14].

While often considered a vital tool, Flow-FISH is a validated supportive test, not an absolute “gold standard” used in isolation. A result below the 1st percentile for your age group strongly suggests a Telomere Biology Disorder, but it must be interpreted alongside your physical symptoms, family history, and genetic findings [15][16]. Results above the 1st percentile do not automatically rule out a TBD, and very short telomeres can sometimes occur in other acquired medical conditions [17][18].

Differentiating DC from Other Conditions

Because low blood counts are common in DC, doctors must rule out other disorders:

  • Fanconi Anemia (FA): Like DC, FA causes inherited bone marrow failure. However, FA is caused by a different cellular problem (DNA repair). Doctors use a chromosome breakage test to distinguish FA from DC [19][20].
  • Acquired Aplastic Anemia: This is an autoimmune condition where the immune system attacks the marrow. Unlike DC, it is not inherited and usually does not involve the specific gene mutations found in TBDs [21][22].

Checklist for Your Diagnostic Report

When you receive your lab and genetic results, look for these specific details to ensure you have a complete picture:

  • [ ] Type of Test: Does it specify “Flow-FISH”? Flow-FISH is generally more precise for diagnosis than qPCR [23].
  • [ ] Cell Subsets: Does the report list lengths for different cell types, such as lymphocytes and granulocytes? [24].
  • [ ] Age-Adjusted Percentile: Does it state your percentile (e.g., “<1st percentile”) rather than just a raw number in “kilobases”? [15].
  • [ ] Variant Classification: For genetic results, is the mutation listed as “Pathogenic” or “Likely Pathogenic”? Note that a negative panel or a “Variant of Uncertain Significance” (VUS) does not definitively rule out a TBD [25][26].
  • [ ] Germline Confirmation: Was the genetic test done on an appropriate sample? While blood is routinely used, if you have an active blood disorder or clonal hematopoiesis, the genetics team may require cultured skin fibroblasts to ensure the results aren’t confounded by acquired blood mutations [18][27].

Common questions in this guide

What tests are used to diagnose dyskeratosis congenita?
Diagnosis combines genetic testing with clinical findings and family history. Flow-FISH measures telomere length in different types of white blood cells, while genetic testing looks for changes in genes involved in telomere maintenance.
What does a Flow-FISH result below the first percentile mean?
A telomere length below the age-adjusted first percentile strongly supports a telomere biology disorder, including dyskeratosis congenita. It is not a diagnosis by itself, and a result above the first percentile does not always rule out the disorder.
Can a negative genetic panel or a VUS rule out dyskeratosis congenita?
No. A negative panel may not detect every disease-causing change, and a variant of uncertain significance means that the finding cannot yet be classified as harmful or harmless. Your genetics team may recommend additional testing or future review.
Does dyskeratosis congenita run in families?
It can, but inheritance depends on the gene involved. Some forms are X-linked, dominant, or recessive, while some variants arise de novo, so a genetic counselor can help determine which relatives may benefit from testing.
How is dyskeratosis congenita distinguished from Fanconi anemia?
Both conditions can cause inherited bone marrow failure, but they result from different cellular problems. A chromosome breakage test is commonly used to help evaluate for Fanconi anemia, while genetic and telomere testing helps assess dyskeratosis congenita.
What should I look for in my genetic and Flow-FISH reports?
Check whether the report identifies the test type, the white blood cell subsets measured, and an age-adjusted telomere percentile. Genetic reports should also state whether a variant is pathogenic, likely pathogenic, or of uncertain significance, and the genetics team may consider whether a blood sample needs confirmation with cultured skin cells.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific gene variant was identified in my (or my child's) report, and how is it classified (Pathogenic, Likely Pathogenic, or VUS)?
  2. 2.Does this inheritance pattern mean other family members need to be tested, and should we involve a genetic counselor?
  3. 3.What was the age-adjusted percentile for my Flow-FISH test, and what cell types were measured?
  4. 4.Can we confirm that Fanconi Anemia has been ruled out using a chromosome breakage test?
  5. 5.If we are considering a bone marrow transplant, how will we screen potential family donors for short telomeres and genetic variants?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (27)
  1. 1

    Dyskeratosis congenita and telomere biology disorders.

    Savage SA

    Hematology. American Society of Hematology. Education Program 2022; (2022(1)):637-648 doi:10.1182/hematology.2022000394.

    PMID: 36485133
  2. 2

    Beginning at the ends: telomeres and human disease.

    Savage SA

    F1000Research 2018; (7()) doi:10.12688/f1000research.14068.1.

    PMID: 29770205
  3. 3

    Triallelic and epigenetic-like inheritance in human disorders of telomerase.

    Collopy LC, Walne AJ, Cardoso S, et al.

    Blood 2015; (126(2)):176-84 doi:10.1182/blood-2015-03-633388.

    PMID: 26024875
  4. 4

    Squamous cell carcinoma of the tongue in 5-year-old girl with dyskeratosis congenita.

    Jh K, Cs K

    International journal of oral and maxillofacial surgery 2021; (50(12)):1546-1549 doi:10.1016/j.ijom.2021.02.027.

    PMID: 33736925
  5. 5

    A Novel Variant and a Missense Variant Identified in the DKC1 Gene in Three Chinese Familieswith Dyskeratosis Congenita.

    Yuan C, Deng D, Yang J, et al.

    Clinical, cosmetic and investigational dermatology 2022; (15()):1837-1845 doi:10.2147/CCID.S371794.

    PMID: 36111181
  6. 6

    Genomic and computational analysis of variants in telomere regulatory genes in subjects with bone marrow failure.

    Shah A, Yadav A, George M, et al.

    European journal of human genetics : EJHG 2026; doi:10.1038/s41431-026-02233-4.

    PMID: 42736390
  7. 7

    Case Series: Clinical Significance of Heterozygous Pathogenic RTEL1 Variants Identified via Routine Clinical Genetic Diagnostics.

    Wedge E, Rasmussen AØ, Borgwardt L, et al.

    American journal of medical genetics. Part A 2026; (200(4)):959-965 doi:10.1002/ajmga.70015.

    PMID: 41332233
  8. 8

    Germline RTEL1 Variants in Telomere Biology Disorders.

    Thompson AS, Niewisch MR, Giri N, et al.

    American journal of medical genetics. Part A 2025; (197(2)):e63882 doi:10.1002/ajmg.a.63882.

    PMID: 39279436
  9. 9

    Compound heterozygous mutations in the helicase RTEL1 causing Hoyeraal-Hreidarsson syndrome with Blake`s pouch cyst: a case report.

    He M, Lian G, Hu H, et al.

    The Turkish journal of pediatrics 2023; (65(5)):845-852.

    PMID: 37853975
  10. 10

    The wide-ranging clinical implications of the short telomere syndromes.

    Barbaro PM, Ziegler DS, Reddel RR

    Internal medicine journal 2016; (46(4)):393-403 doi:10.1111/imj.12868.

    PMID: 26247919
  11. 11

    A novel homozygous RTEL1 variant in a consanguineous Lebanese family: phenotypic heterogeneity and disease anticipation.

    Gutierrez-Rodrigues F, Masri N, Chouery E, et al.

    Human genetics 2019; (138(11-12)):1323-1330 doi:10.1007/s00439-019-02076-8.

    PMID: 31677132
  12. 12

    Clinical manifestations of telomere biology disorders in adults.

    Niewisch MR, Beier F, Savage SA

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):563-572 doi:10.1182/hematology.2023000490.

    PMID: 38066848
  13. 13

    Assessment of Telomere Length, Phenotype, and DNA Content.

    Kelesidis T, Schmid I

    Current protocols in cytometry 2017; (79()):7.26.1-7.26.23 doi:10.1002/cpcy.12.

    PMID: 28055113
  14. 14

    Telomere content measurement in human hematopoietic cells: Comparative analysis of qPCR and Flow-FISH techniques.

    Wand T, Fang M, Chen C, et al.

    Cytometry. Part A : the journal of the International Society for Analytical Cytology 2016; (89(10)):914-921 doi:10.1002/cyto.a.22982.

    PMID: 27717244
  15. 15

    Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita.

    Khincha PP, Bertuch AA, Gadalla SM, et al.

    Blood advances 2018; (2(11)):1243-1249 doi:10.1182/bloodadvances.2018016964.

    PMID: 29853525
  16. 16

    Correlation of Leukocyte Telomere Length Measurement Methods in Patients with Dyskeratosis Congenita and in Their Unaffected Relatives.

    Khincha PP, Dagnall CL, Hicks B, et al.

    International journal of molecular sciences 2017; (18(8)) doi:10.3390/ijms18081765.

    PMID: 28805708
  17. 17

    Clinical Impact of Telomere Length Testing for Interstitial Lung Disease.

    Zhang D, Eckhardt CM, McGroder C, et al.

    Chest 2024; (166(5)):1071-1081 doi:10.1016/j.chest.2024.06.006.

    PMID: 38950694
  18. 18

    Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria.

    Tometten M, Kirschner M, Meyer R, et al.

    HemaSphere 2023; (7(5)):e874 doi:10.1097/HS9.0000000000000874.

    PMID: 37096215
  19. 19

    Genetic variant profile in a cohort of inherited bone marrow failure patients from North india.

    Viswanathan GK, Dass J, Chauhan R, et al.

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2026; (42(5)):1873-1880 doi:10.1007/s12288-025-02243-0.

    PMID: 42712617
  20. 20

    Genetics and genomics of bone marrow failure syndrome.

    Kim HY, Kim HJ, Kim SH

    Blood research 2022; (57(S1)):86-92 doi:10.5045/br.2022.2022056.

    PMID: 35483932
  21. 21

    Hereditary Predispositions to Myelodysplastic Syndrome.

    Bannon SA, DiNardo CD

    International journal of molecular sciences 2016; (17(6)).

    PMID: 27248996
  22. 22

    Cytogenetics in the management of bone marrow failure syndromes: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).

    Cuccuini W, Collonge-Rame MA, Auger N, et al.

    Current research in translational medicine 2023; (71(4)):103423 doi:10.1016/j.retram.2023.103423.

    PMID: 38016422
  23. 23

    Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies.

    Ferreira MSV, Kirschner M, Halfmeyer I, et al.

    Annals of the New York Academy of Sciences 2020; (1466(1)):93-103 doi:10.1111/nyas.14248.

    PMID: 31647584
  24. 24

    The diagnostic performance of the basic versus the detailed telomere Flow FISH test in young patients with aplastic anaemia.

    DeCleene NF, Nguyen DT, Kirk SE, et al.

    British journal of haematology 2026; (208(3)):1093-1104 doi:10.1111/bjh.70155.

    PMID: 40988089
  25. 25

    Telomere biology disorders may manifest as common variable immunodeficiency (CVID).

    Rolles B, Caballero-Oteyza A, Proietti M, et al.

    Clinical immunology (Orlando, Fla.) 2023; (257()):109837 doi:10.1016/j.clim.2023.109837.

    PMID: 37944684
  26. 26

    Functional genomics for curation of variants in telomere biology disorder associated genes: A systematic review.

    Nelson N, Feurstein S, Niaz A, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2023; (25(3)):100354 doi:10.1016/j.gim.2022.11.021.

    PMID: 36496180
  27. 27

    Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita.

    Kirschner M, Maurer A, Wlodarski MW, et al.

    Leukemia 2018; (32(8)):1762-1767 doi:10.1038/s41375-018-0125-x.

    PMID: 29749397

This page explains dyskeratosis congenita genetic and telomere testing for informational purposes only and does not constitute medical advice. A genetics specialist, hematologist, or genetic counselor should interpret your results in the context of your symptoms and family history.

Get notified when new evidence is published on Dyskeratosis congenita.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.